Skip to content

Tramadol-paracetamol Combination in Treatment of Patients Undergoing Spinal Surgery

Tramadol-paracetamol Combination in Treatment of Patients Undergoing Spinal Surgery

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04533009
Acronym
TRAMAPARAS
Enrollment
120
Registered
2020-08-31
Start date
2020-02-01
Completion date
2024-12-31
Last updated
2023-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Brief summary

Tramadol-paracetamol combination is studied in patients coming for elective spine surgery. The study drug is started at the day of surgery and continued maximum of five days. Before the surgery pain, use of pain medication, satisfaction for pain medication, adverse effects, resilience, depression and life satisfaction were asked. At the discharge and seven days after the surgery use of pain medication and adverse effects were asked. The patients were followed up to 28 days and one year after surgery.

Interventions

PROCEDUREspine surgery

Tramadol-paracetamol 325mg/37,5mg two tablets twice daily

Sponsors

University of Eastern Finland
CollaboratorOTHER
Kuopio University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

placebo tablets are used

Intervention model description

Randomised, double blinded, placebo controlled study

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* age 18-75 years, * BMI 18-35 kg/m2, * informed consent obtained, * elective spine surgery

Exclusion criteria

* Age\<18 years or \>75 years * Hypersensitivity to anti-inflammatory drugs, paracetamol, tramadol or their auxiliary substances * Acute or recovered hemorrhage in gastrointestinal tract or peptic ulcer * Hemorrhagic disease * Monoamineoxidase use in past two weeks * Epilepsy * Tendency to seizure * Anti-seizure drugs in use Liver or renal failure Reduction in lung function Alcohol, drug or opioid addiction on record Acute intoxication due to alcohol, analgesics, opioids or psychopharmacon Pregnancy or breastfeeding Investigators estimation

Design outcomes

Primary

MeasureTime frameDescription
Satisfaction for pain medicationone week after surgerysatisfaction measured with numeral rating scale 0-10 (0=not satisfied, 10= totally satisfied

Secondary

MeasureTime frameDescription
need for rescue pain medicationone week after surgeryMeasured as amount of other pain medicines used as rescue medicine
Pain assessmentone week after surgeryPain measered in numeral rating scale 0-10 (0= no pain, 10=worst pain)
adverse effectsone week after surgeryPatient reported adverse reactions

Other

MeasureTime frameDescription
Pain assessmentone year after surgeryPain measered in numeral rating scale 0-10 (0= no pain, 10=worst pain)

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026